These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34990780)

  • 21. Utilizing relative potency factors (RPF) and threshold of toxicological concern (TTC) concepts to assess hazard and human risk assessment profiles of environmental metabolites: a case study.
    Terry C; Rasoulpour RJ; Knowles S; Billington R
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):301-17. PubMed ID: 25584438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation risk assessment of chemicals - Rolling out a human-centric testing strategy to drive 3R implementation: The RISK-HUNT3R project perspective.
    Pallocca G; Moné MJ; Kamp H; Luijten M; Van de Water B; Leist M
    ALTEX; 2022; 39(3):419–426. PubMed ID: 35404467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
    Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
    Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop.
    Ellison CA; Blackburn KL; Carmichael PL; Clewell HJ; Cronin MTD; Desprez B; Escher SE; Ferguson SS; Grégoire S; Hewitt NJ; Hollnagel HM; Klaric M; Patel A; Salhi S; Schepky A; Schmitt BG; Wambaugh JF; Worth A
    Regul Toxicol Pharmacol; 2019 Apr; 103():63-72. PubMed ID: 30653989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety assessment of cosmetics by read across applied to metabolomics data of in vitro skin and liver models.
    Jacques C; Jamin EL; Jouanin I; Canlet C; Tremblay-Franco M; Martin JF; Zalko D; Brunel Y; Bessou-Touya S; Debrauwer L; Ferret PJ; Duplan H
    Arch Toxicol; 2021 Oct; 95(10):3303-3322. PubMed ID: 34459931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current opinion on risk assessment of cosmetics.
    Kim KB; Kwack SJ; Lee JY; Kacew S; Lee BM
    J Toxicol Environ Health B Crit Rev; 2021 May; 24(4):137-161. PubMed ID: 33832410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans.
    Geci R; Gadaleta D; de Lomana MG; Ortega-Vallbona R; Colombo E; Serrano-Candelas E; Paini A; Kuepfer L; Schaller S
    Arch Toxicol; 2024 May; ():. PubMed ID: 38722347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skin sensitisation prediction using read-across, an illustrative next generation risk assessment (NGRA) case study for vanillin.
    Gautier F; Assaf Vandecasteele H; Tourneix F; van Vliet E; Alépée N; Bury D
    Regul Toxicol Pharmacol; 2023 Sep; 143():105458. PubMed ID: 37453556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next generation risk assessment for skin allergy: Decision making using new approach methodologies.
    Gilmour N; Reynolds J; Przybylak K; Aleksic M; Aptula N; Baltazar MT; Cubberley R; Rajagopal R; Reynolds G; Spriggs S; Thorpe C; Windebank S; Maxwell G
    Regul Toxicol Pharmacol; 2022 Jun; 131():105159. PubMed ID: 35311660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advancing food safety risk assessment in China: development of new approach methodologies (NAMs).
    Yang D; Yang H; Shi M; Jia X; Sui H; Liu Z; Wu Y
    Front Toxicol; 2023; 5():1292373. PubMed ID: 38046399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next generation risk assessment: an
    Ebmeyer J; Najjar A; Lange D; Boettcher M; Voß S; Brandmair K; Meinhardt J; Kuehnl J; Hewitt NJ; Krueger CT; Schepky A
    Front Pharmacol; 2024; 15():1345992. PubMed ID: 38515841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Making in silico predictive models for toxicology FAIR.
    Cronin MTD; Belfield SJ; Briggs KA; Enoch SJ; Firman JW; Frericks M; Garrard C; Maccallum PH; Madden JC; Pastor M; Sanz F; Soininen I; Sousoni D
    Regul Toxicol Pharmacol; 2023 May; 140():105385. PubMed ID: 37037390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients.
    Dent MP; Vaillancourt E; Thomas RS; Carmichael PL; Ouedraogo G; Kojima H; Barroso J; Ansell J; Barton-Maclaren TS; Bennekou SH; Boekelheide K; Ezendam J; Field J; Fitzpatrick S; Hatao M; Kreiling R; Lorencini M; Mahony C; Montemayor B; Mazaro-Costa R; Oliveira J; Rogiers V; Smegal D; Taalman R; Tokura Y; Verma R; Willett C; Yang C
    Regul Toxicol Pharmacol; 2021 Oct; 125():105026. PubMed ID: 34389358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of connectivity mapping to support read across: A deeper dive using data from 186 chemicals, 19 cell lines and 2 case studies.
    De Abrew KN; Shan YK; Wang X; Krailler JM; Kainkaryam RM; Lester CC; Settivari RS; LeBaron MJ; Naciff JM; Daston GP
    Toxicology; 2019 Jul; 423():84-94. PubMed ID: 31125584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A workflow to practically apply true dose considerations to in vitro testing for next generation risk assessment.
    Nicol B; Vandenbossche-Goddard E; Thorpe C; Newman R; Patel H; Yates D
    Toxicology; 2024 Jun; 505():153826. PubMed ID: 38719068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making.
    Paini A; Leonard JA; Joossens E; Bessems JGM; Desalegn A; Dorne JL; Gosling JP; Heringa MB; Klaric M; Kliment T; Kramer NI; Loizou G; Louisse J; Lumen A; Madden JC; Patterson EA; Proença S; Punt A; Setzer RW; Suciu N; Troutman J; Yoon M; Worth A; Tan YM
    Comput Toxicol; 2019 Feb; 9():61-72. PubMed ID: 31008414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporating lines of evidence from New Approach Methodologies (NAMs) to reduce uncertainties in a category based read-across: A case study for repeated dose toxicity.
    Pestana CB; Firman JW; Cronin MTD
    Regul Toxicol Pharmacol; 2021 Mar; 120():104855. PubMed ID: 33359265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk assessment in the 21st century: where are we heading?
    Brescia S; Alexander-White C; Li H; Cayley A
    Toxicol Res (Camb); 2023 Feb; 12(1):1-11. PubMed ID: 36866215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of read-across and computer-based predictive analysis for the safety assessment of PEG cocamines.
    Skare JA; Blackburn K; Wu S; Re TA; Duche D; Ringeissen S; Bjerke DL; Srinivasan V; Eisenmann C
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):515-28. PubMed ID: 25659490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.